CLINICAL NEPHROLOGY: Edited by David S. GoldfarbVitamin D in chronic kidney disease is there a role outside of PTH control?Brogan, Maureena; Astor, Brad C.b; Melamed, Michal L.aAuthor Information aDepartment of Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York bDepartments of Medicine and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA Correspondence to Michal L. Melamed, MD, MHS, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann 615, Bronx, NY 10461, USA. Tel: +1 718 430 2304; fax: +1 718 430 8963; e-mail: firstname.lastname@example.org Current Opinion in Nephrology and Hypertension: March 2020 - Volume 29 - Issue 2 - p 243-247 doi: 10.1097/MNH.0000000000000591 Buy Metrics Abstract Purpose of review Vitamin D deficiency is common in patients with kidney disease and many patients receive vitamin D supplementation. Several large, well-designed clinical trials have been published in the last few years evaluating the effects of vitamin D supplementation on important outcomes for patients with kidney disease including effects on cardiovascular disease, secondary hyperparathyroidism, and kidney disease progression. Recent findings Several negative trials have been published showing no effect of cholecalciferol supplementation on cardiovascular events, kidney disease progression, and albuminuria. Long-term supplementation does not appear to be associated with kidney stone disease. Vitamin D supplementation decreases parathyroid hormone (PTH) levels and high levels of 25-hydroxyvitamin D may be required for maximal suppression. Summary There appear to be no effects of vitamin D supplementation on noncalcemic outcomes including progression of kidney disease, albuminuria, or cardiovascular disease. The primary reason to use vitamin D in kidney disease remains to lower PTH levels. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.